Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes

About this update from Elicio Therapeutics, Inc.

BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the Company was added to the Russell 2000® and Russell 3000® Indexes, effective after the U.S. market close on June 26, 2026, as part of the 2026 Russell indexes annual reconstitution. "Inclusion of Elicio Therapeutics in the Russell 2000® and Russell 3000® Indexes is a meaningful milestone that reflects the growing recognition of the Company's progress," said Robert Connelly, Chief Executive Officer of Elicio Therapeutics. "As we continue to advance our ELI-002 7P program forward, this inclusion broadens our visibility with institutional investors and underscores our ongoing commitment to delivering meaningful value for patients and shareholders." The Russell 3000® Index tracks the performance of the largest 3,000 publicly traded U.S. companies and serves as a broad benchmark for the U.S. equity market. The Russell 2000® Index, a subset of the Russell 3000®, measures the performance of small-cap stocks and represents approximately 10% of the total market capitalization of the U.S. equity market. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $12.2 trillion in assets are benchmarked to or invested in products based on the Russell US indexes. Russell indexes are part of FTSE Russell, a global index leader that provides innovative benchmarking, analytics, and data solutions for investors worldwide. For further information on the Russell indexes, please visit the FTSE Russell website. About ELI-002 Elicio's lead product candidate, ELI-002, is a structurally novel investigational AMP cancer immunotherapy that targets cancers that are driven by mutations in the KRAS-gene—a prevalent driver of many human cancers. ELI-002 is comprised of two powerful components that are built with Elicio's proprietary AMP technology consisting of AMP-modified mutant KRAS peptide antigens and ELI-004, an AMP-modified CpG oligodeoxynucleotide adjuvant that is available as an off-the-shelf subcutaneous administration. ELI-002 7P (7-peptide formulation) was evaluated in the randomized Phase 2 AMPLIFY-7P trial in patients with mKRAS...

View stock analysis, news, and events for Elicio Therapeutics, Inc.